Koe B K, Lebel L A, Welch W M
Central Research Division, Pfizer Inc., Groton, CT 06340.
Psychopharmacology (Berl). 1990;100(4):470-6. doi: 10.1007/BF02243998.
Tritiated sertraline, a radiolabeled form of a potent and selective inhibitor of serotonin uptake, was found to bind with high affinity to rat whole brain membranes. Characterization studies showed that [3H] sertraline binding occurred at a single site with the following parameters: KD 0.57 nM, Bmax 821 fmol/mg protein, nH 1.06. This binding was reversible; the dissociation constant calculated from kinetic measurements (KD 0.81 nM) agreed with that determined by saturation binding experiments. [3H] Sertraline binding in the presence of serotonin, paroxetine, fluoxetine or imipramine suggested competitive inhibition of binding (large increase in KD with little change in Bmax). The rank order of potency of inhibition of [3H] sertraline binding was similar to that of inhibition of serotonin uptake for known uptake inhibitors and the 1-amino-4-phenyltetralin uptake blockers. A marked decrease in ex vivo [3H] sertraline binding in the brain of rats 7 days after treatment with p-chloroamphetamine was consistent with the loss of serotonin uptake sites induced by this agent. The results of our study indicated that [3H] sertraline labels serotonin uptake sites in rat brain.
氚标记的舍曲林是一种有效的、选择性的5-羟色胺摄取抑制剂的放射性标记形式,被发现能与大鼠全脑膜以高亲和力结合。特性研究表明,[3H]舍曲林结合发生在单一部位,其参数如下:解离常数(KD)为0.57纳摩尔,最大结合容量(Bmax)为821飞摩尔/毫克蛋白,Hill系数(nH)为1.06。这种结合是可逆的;从动力学测量计算出的解离常数(KD为0.81纳摩尔)与通过饱和结合实验确定的解离常数一致。在5-羟色胺、帕罗西汀、氟西汀或丙咪嗪存在的情况下,[3H]舍曲林结合表明存在结合的竞争性抑制(KD大幅增加,而Bmax变化很小)。对于已知的摄取抑制剂和1-氨基-4-苯基四氢萘摄取阻滞剂,抑制[3H]舍曲林结合的效力顺序与抑制5-羟色胺摄取的顺序相似。在用对氯苯丙胺治疗7天后,大鼠脑中离体[3H]舍曲林结合显著下降,这与该药物诱导的5-羟色胺摄取位点丧失一致。我们的研究结果表明,[3H]舍曲林标记大鼠脑中的5-羟色胺摄取位点。